Table 3 Antiviral treatment
|  | Received treatment (N = 18) | Untreated (N = 11) |
|---|---|---|
Media age (IQR)—years | 47.5 (45–55.7) | 39 (35–53) |
Female sex—n (%) | 13 (72.2%) | 5 (45.4%) |
Covid-19 pneumonia—n (%) | 11 (61.1%) | 4 (36.3%) |
Covid-19 severity—n (%) |  |  |
 Mild | 5 (27.7%) | 2 (18.1%) |
 Moderate | 4 (22.2%) | 2 (18.1%) |
 Severe | 9 (50%) | 7 (63.6%) |
COVID-19 acute antiviral treatment—n (%) | 13 (72.2%) | 6 (54.5%) |
Positive results of plasma PCR—n (%) | 9 (50%) | 4 (36%) |
At least one positive PCR—n (%) | 10 (55.5%) | 5 (45.4%) |
Basal functional status | Â | Â |
 Grade 0—n (%) | 0 (0%) | 0 (0%) |
 Grade I—n (%) | 1 (5.5%) | 6 (54.54%) |
 Grade II—n (%) | 5 (27.7%) | 3 (27.27%) |
 Grade III—n (%) | 4 (22.2%) | 1 (9%) |
 Grade IV—n (%) | 8 (44.4%) | 1 (9%) |